PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022 - KTRE.com | Lufkin and Nacogdoches, Texas

PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, Feb. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p02013608/PharmaPoint-Microvascular-Complications-of-Diabetes---US-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022

Summary

The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

The base-year market leader in the US is Roche/Novartis' Lucentis, with $497m in sales, as the drug is the first-to-market anti-VEGF inhibitor approved for the treatment of DME. Lucentis will face stiff competition in Regeneron/Bayer's Eylea, which is currently in Phase III trials for DME.

Scope

- Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US MCD market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for MCD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
3 Disease Overview 15
3.1 Etiology and Pathophysiology 17
3.1.1 Diabetic Nephropathy 17
3.1.2 Diabetic Retinopathy 19
3.1.3 Diabetic Neuropathy 20

3.2 Prognosis 21
3.3 Quality of Life 22
3.4 Symptoms 23
4 Disease Management 24
4.1 Treatment Overview 24
4.1.1 Diagnosis and Referrals 24
4.1.2 Screening 26
4.1.3 Treatment Guidelines 27
4.2 US 34
4.2.1 Diagnosis 34
4.2.2 Clinical Practice 36
5 Competitive Assessment 38
5.1 Overview 38
5.2 Strategic Competitor Assessment 39
5.3 Diabetic Nephropathy: Product Profiles - Major Classes and Brands 43
5.3.1 Angiotensin-Converting Enzyme (ACE) Inhibitors 43
5.3.2 Angiotensin Receptor Blockers 46
5.4 Diabetic Retinopathy: Product Profiles - Major Classes and Brands 49
5.4.1 Lucentis (ranibizumab) 49
5.4.2 Avastin (bevacizumab) 53
5.4.3 Corticosteroid Intravitreal Implants 58
5.5 Diabetic Neuropathy: Product Profiles - Major Classes and Brands 61
5.5.1 Tricyclic Antidepressants 61
5.5.2 Serotonin-Norepinephrine Reuptake Inhibitors - Cymbalta (duloxetine) and Effexor (venlafaxine) 64

5.5.3 Anticonvulsants - Neurontin (gabapentin) and Lyrica (pregabalin) 68
5.5.4 Opioids 73
6 Opportunity and Unmet Need 76
6.1 Overview 76
6.2 Unmet Needs 77
6.2.1 Unified Treatment for the Microvascular Complications of Diabetes 77
6.2.2 Optimization of Personalized Therapy in the Microvascular Complications of Diabetes 77
6.2.3 Treatment for Diabetic Nephropathy that Would Prevent ESRD 79
6.2.4 Cardio- and Renoprotective Therapy for Diabetic Nephropathy 80
6.2.5 Efficient Therapy for Retinopathy 81
6.2.6 Convenient Administration in Diabetic Retinopathy Treatment 81
6.2.7 Treatment for Diabetic Neuropathy 82
6.3 Unmet Needs Gap Analysis 83
6.4 Opportunity: Therapy for the Underlying Cause of the Microvascular Complications of Diabetes 85
6.5 Opportunity: Patient-Tailored Therapy for the Microvascular Complications of Diabetes 85
6.6 Opportunity: Efficacious Therapy for Diabetic Nephropathy 86
6.7 Opportunity: Topical Treatment for Diabetic Retinopathy 86
6.8 Opportunity: Treatment for Diabetic Neuropathy 87
7 Pipeline Assessment 88
7.1 Overview 88
7.2 Promising Drugs in Clinical Development 91
7.2.1 Eylea (aflibercept) 93
7.2.2 Optina (danazol) 98
7.2.3 Atrasentan Hydrochloride 103
7.2.4 Ranirestat 107
8 Market Outlook 111

8.1 US 111
8.1.1 Forecast 111
8.1.2 Key Events 116
8.1.3 Drivers and Barriers 116
9 Appendix 119
9.1 Bibliography 119
9.2 Abbreviations 132
9.3 Methodology 137
9.4 Forecasting Methodology 137
9.4.1 Diagnosed Patients 137
9.4.2 Percent Drug-Treated Patients 138
9.4.3 Drugs Included in Each Therapeutic Class 138
9.4.4 Launch and Patent Expiry Dates 139
9.4.5 General Pricing Assumptions 139
9.4.6 Individual Drug Assumptions 140
9.4.7 Generic Erosion 144
9.4.8 Pricing of Pipeline Agents 144
9.5 Physicians and Specialists Included in this Study 145
9.6 About the Authors 147
9.6.1 Analyst II - CVMD 147

9.6.2 Therapy Director - CVMD and Infectious Disease 147
9.6.3 Global Head of Healthcare 148
9.7 About GlobalData 149
9.8 Disclaimer 149

1.1 List of Tables

Table 1: Risk Factors for MCD 17
Table 2: Symptoms of MCD 23
Table 3: Diagnostic Tests and Typical Criteria for MCD 25
Table 4: Treatment Guidelines for MCD 28
Table 5: Most Prescribed Drugs for MCD by Class in the 7MM, 2012 31
Table 6: Leading Drug Treatments for MCD, 2013 41
Table 7: ACE Inhibitors SWOT Analysis, 2013 45
Table 8: ARBs SWOT Analysis, 2013 48
Table 9: Product Profile - Lucentis 50
Table 10: Lucentis SWOT Analysis, 2013 53
Table 11: Product Profile - Avastin 55
Table 12: Avastin SWOT Analysis, 2013 57
Table 13: Corticosteroid Intravitreal Implants SWOT Analysis, 2013 60
Table 14: TCAs SWOT Analysis , 2013 63
Table 15: Product Profile - Cymbalta 65

Table 16: Product Profile - Effexor 65
Table 17: Cymbalta SWOT Analysis, 2013 67
Table 18: Product Profile - Neurontin (gabapentin) 70
Table 19: Product Profile - Lyrica (pregabalin) 70
Table 20: Lyrica SWOT Analysis, 2013 72
Table 21: Opioids SWOT Analysis, 2013 75
Table 22: Overall Unmet Needs - Current Level of Attainment 76
Table 23: Clinical Unmet Needs in MCD - Gap Analysis, 2012 84
Table 24: MCD - Clinical Trials by Phase and Status, 2013 90
Table 25: MCD - Phase Pipeline, 2013 91
Table 26: Comparison of Drugs in Development for MCD, 2013 92
Table 27: Product Profile - Eylea 94
Table 28: Eylea SWOT Analysis, 2013 98
Table 29: Product Profile - Optina 100
Table 30: Optina SWOT Analysis, 2013 102
Table 31: Product Profile - Atrasentan 104
Table 32: Atrasentan SWOT Analysis, 2013 106
Table 33: Product Profile - Ranirestat 108
Table 34: Ranirestat SWOT Analysis, 2013 110
Table 35: US Sales Forecasts ($) for MCD, 2012-2022 112
Table 36: Key Events Impacting Sales for MCD in the US, 2012-2022 116
Table 37: MCD Market - Drivers and Barriers in the US, 2013 116
Table 38: Key Launch Dates 139
Table 39: Key Patent Expiries 139
Table 40: Number of High-Prescribing Physicians Surveyed 146

List of Figures

Figure 1: Potential Mechanisms of Diabetes-Induced Microvascular Complications 16
Figure 2: General Treatment Algorithms for MCD 29
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in MCD, 2012-2022 92
Figure 4: Sales for Diabetic Nephropathy in the US, 2012-2022 113
Figure 5: Sales for Diabetic Retinopathy in the US, 2012-2022 114
Figure 6: Sales for Diabetic Neuropathy in the US, 2012-2022 115

To order this report: PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p02013608/PharmaPoint-Microvascular-Complications-of-Diabetes---US-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
KTRE logo

KTRE

358 TV Road,
Pollok TX 75969

FCC Public File
publicfile@ktre.com
936-853-8639
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KTRE. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.